<DOC>
	<DOCNO>NCT00355901</DOCNO>
	<brief_summary>To assess effect visilizumab safety subsequent salvage therapy subject experienced disease progression previous visilizumab study subsequently receive salvage therapy .</brief_summary>
	<brief_title>An Observational Follow-up Study Subjects Receiving Salvage Therapy After Previous Treatment Visilizumab Study Intravenous Steroid-Refractory Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Previous participation visilizumab study IVSRUC . Disease progression enrol previous visilizumab study , subsequent treatment salvage therapy . Unable understand purpose risk study , unwilling unable provide sign date informed consent . For U.S. site , unwilling unable provide authorization use protect health information .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>Colitis</keyword>
	<keyword>Steroid-Refractory</keyword>
	<keyword>Visilizumab</keyword>
	<keyword>Intravenous Steroid-Refractory Ulcerative Colitis ( IVSR-UC )</keyword>
</DOC>